Company Overview
Oragenics, Inc. is focused on developing effective treatments for oral mucositis and becoming a leader in developing novel antibiotics against infectious diseases. Oragenics, Inc. has established exclusive worldwide channel collaborations with Precigen, Inc., a synthetic biology company. The collaborations allow Oragenics access to Precigen's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and new therapeutic probiotics designed to alleviate symptoms from oral diseases.
Recent News
Oragenics Issues Letter to Stockholders
Stock Overview
01/15/2021 04:00 PM EST
Investor Relations
CORE IR
John Marco
Managing Director
T: 310-819-2948
johnm@coreir.com